000			02086nam a22004455i 4500
001			978-3-642-14816-3
003			DE-He213
005			20140220083746.0
007			cr nn 008mamaa
008			101029s2011 gw | s |||| 0|eng d
020			_a9783642148163 _9978-3-642-14816-3
024	7		_a10.1007/978-3-642-14816-3 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
100	1		_aRommel, Christian. _eeditor.
245	1	0	_aPhosphoinositide 3-kinase in Health and Disease _h[electronic resource] : _bVolume 2 / _cedited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg : _bImprint: Springer, _c2011.
300			_aX, 306 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v347
520			_aFrom humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
650		0	_aMedicine.
650		0	_aOncology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
700	1		_aVanhaesebroeck, Bart. _eeditor.
700	1		_aVogt, Peter K. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783642148156
830		0	_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v347
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-642-14816-3
912			_aZDB-2-SBL
999			_c106997 _d106997